中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2012年
33期
8-9
,共2页
乙型肝炎病毒%替比夫定%母婴垂直传播hBV-DNA
乙型肝炎病毒%替比伕定%母嬰垂直傳播hBV-DNA
을형간염병독%체비부정%모영수직전파hBV-DNA
Hepatitis B virus%Telbivudine%Vertical transmission%hBV-DNA
目的通过观察替比夫定阻断高病毒载量乙肝携带孕妇母婴垂直传播效果,探讨妊娠期抗病毒治疗对乙型肝炎母婴传播的阻断意义和疗效。方法2011年10月至2012年4月,我院门诊检查HBsAg阳性孕妇测定其血清HBV-DNA含量均在106拷贝/ml以上的病例20例,随机分为两组,实验组12例于妊娠28周至分娩期间一直服用替比夫定600mg,1次/天,对照组8例不用药物干预。观察所有孕妇孕期和分娩前HBV-DNA含量、HBV血清标志物情况。检测分娩后新生儿脐血中HBV-DNA含量、HBV标志物情况。结果20例乙肝病毒携带的孕妇中,实验组11例未检出HBV-DNA(<5×102拷贝/ml),1例HBV-DNA降至103拷贝/ml,对照组8例检出HBV-DNA仍维持在106拷贝/ml以上,所有新生儿均发育正常,实验组12例新生儿脐血中HBV-DNA<5×102拷贝/ml,HBsAg呈阴性。对照组仅1例新生儿脐血中HBV-DNA<5×102拷贝/ml,HBsAg呈阴性。结论替比夫定可以显著降低HBV-DNA载量,降低新生儿宫内感染几率,对阻断母婴HBV垂直传播有效。
目的通過觀察替比伕定阻斷高病毒載量乙肝攜帶孕婦母嬰垂直傳播效果,探討妊娠期抗病毒治療對乙型肝炎母嬰傳播的阻斷意義和療效。方法2011年10月至2012年4月,我院門診檢查HBsAg暘性孕婦測定其血清HBV-DNA含量均在106拷貝/ml以上的病例20例,隨機分為兩組,實驗組12例于妊娠28週至分娩期間一直服用替比伕定600mg,1次/天,對照組8例不用藥物榦預。觀察所有孕婦孕期和分娩前HBV-DNA含量、HBV血清標誌物情況。檢測分娩後新生兒臍血中HBV-DNA含量、HBV標誌物情況。結果20例乙肝病毒攜帶的孕婦中,實驗組11例未檢齣HBV-DNA(<5×102拷貝/ml),1例HBV-DNA降至103拷貝/ml,對照組8例檢齣HBV-DNA仍維持在106拷貝/ml以上,所有新生兒均髮育正常,實驗組12例新生兒臍血中HBV-DNA<5×102拷貝/ml,HBsAg呈陰性。對照組僅1例新生兒臍血中HBV-DNA<5×102拷貝/ml,HBsAg呈陰性。結論替比伕定可以顯著降低HBV-DNA載量,降低新生兒宮內感染幾率,對阻斷母嬰HBV垂直傳播有效。
목적통과관찰체비부정조단고병독재량을간휴대잉부모영수직전파효과,탐토임신기항병독치료대을형간염모영전파적조단의의화료효。방법2011년10월지2012년4월,아원문진검사HBsAg양성잉부측정기혈청HBV-DNA함량균재106고패/ml이상적병례20례,수궤분위량조,실험조12례우임신28주지분면기간일직복용체비부정600mg,1차/천,대조조8례불용약물간예。관찰소유잉부잉기화분면전HBV-DNA함량、HBV혈청표지물정황。검측분면후신생인제혈중HBV-DNA함량、HBV표지물정황。결과20례을간병독휴대적잉부중,실험조11례미검출HBV-DNA(<5×102고패/ml),1례HBV-DNA강지103고패/ml,대조조8례검출HBV-DNA잉유지재106고패/ml이상,소유신생인균발육정상,실험조12례신생인제혈중HBV-DNA<5×102고패/ml,HBsAg정음성。대조조부1례신생인제혈중HBV-DNA<5×102고패/ml,HBsAg정음성。결론체비부정가이현저강저HBV-DNA재량,강저신생인궁내감염궤솔,대조단모영HBV수직전파유효。
Objective To observe the efficacy of telbivudine for preventingmother-to-infanthBV vertical transmission inhighhBV-DNA infected pregnant wo-men.Methods From October 2011 to April 2012,20 chronichBsAg positive pregnant women with ahighhBV-DNA level(>106copies/ml) and their newborn infants by vertical transmission entered the study.The women randomlydivided into twogroups: testgroup and contrastgroup.The testgroup 12 pregnant women were treated with oral telbivudine 600mg oncedaily between 28 weeks after labour.The contrastgroup were notdrug intervention.The changes in thehBV-DNA level of all pregnant women were observed.The neonates cord bloodhBV-DNA level andhBV serummarkers weredetected.Results Of the 20 pregnant women, the testgroup 11 pregnant women’shBV-DNA levels were notdetected (<5×102copies/ml).One pregnant woman’shBV-DNA level was 2.33×103copies/ml.Yet The contrastgroup 8 caseshBV-DNA level was still above 106copies/ml.The neonates were normallydeveloped, The testgroup neonateshBV-DHA levels were<5×102copies/ml, and theirhBsAg tests were negative.But the contrastgrouphad same results only one.Conclusion Telbivudine seems to be effective in the preventing ofmother-to-infanthBV vertical transmission, it can lowerhBV-DNA viral load and reduce the neonatal palace risk.
